Visceral leishmaniasis treatment, Italy
2003

Visceral Leishmaniasis Treatment in Italy

Sample size: 573 publication Evidence: moderate

Author Information

Author(s): Gradoni Luigi, Gramiccia Marina, Scalone Aldo

Primary Institution: Istituto Superiore di Sanità

Hypothesis

The study aimed to assess changes in first-line drug regimens for visceral leishmaniasis in Italy after the introduction of lipid-associated amphotericin B.

Conclusion

The study found a significant shift in treatment from meglumine antimoniate to liposomal amphotericin B over a 16-year period in Italy.

Supporting Evidence

  • The proportion of patients treated with meglumine antimoniate decreased from 100% to 2.8% over the study period.
  • Liposomal amphotericin B became the primary treatment option, accounting for 97.2% of cases by 2001.
  • Treatment failures with meglumine antimoniate increased significantly in recent years.

Takeaway

Doctors in Italy used to treat a disease called visceral leishmaniasis with one medicine, but now they mostly use a different one that works better.

Methodology

A retrospective analysis of treatment data from patients diagnosed with visceral leishmaniasis at the Istituto Superiore di Sanità in Rome.

Potential Biases

There may be biases due to the lack of an official drug policy for visceral leishmaniasis therapy in Italy.

Limitations

The study did not include immunosuppressed patients, who typically respond poorly to treatments.

Participant Demographics

The study included 573 immunocompetent patients, with a significant proportion being children.

Statistical Information

P-Value

0.01

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3201/eid0912.030178

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication